**Supplementary Table 2** Anti-emetic treatment-related adverse events of incidence ≥10% in at least one

 study arm (any grade) over cycle 1

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Event** | **Ola arma****(n=27)** | **Ola + Dex arma****(n=27)** | **Dex arma****(n=27)** | ***P*-valueb** |
| Constipation | 9 (33.3) | 15 (55.6) | 13 (48.1) | 0.266 |
| Diarrhoea | 1 (3.7) | 2 (7.4) | 4 (14.8) | 0.490 |
| Somnolence | 21 (77.8) | 24 (88.9) | 20 (74.1) | 0.397 |
| Headache | 2 (7.4) | 3 (11.1) | 4 (14.8) | 0.904 |
| Insomnia | 4 (14.8) | 2 (7.4) | 5 (18.5) | 0.606 |

Ola, olanzapine; Dex, dexamethasone.

Data are presented as numbers (percentages).

No grade 3-4 adverse events were observed in each study arm.

aPatients received the combination of palonosetron, dexamethasone, and olanzapine on day 1.

bCalculated using the Fisher-Freeman-Halton exact test (two-sided) for the overall comparison among the three arms.